WO2001039793A3 - Pharmaceutical compositions containing sema7a polypeptides - Google Patents

Pharmaceutical compositions containing sema7a polypeptides Download PDF

Info

Publication number
WO2001039793A3
WO2001039793A3 PCT/EP2000/011873 EP0011873W WO0139793A3 WO 2001039793 A3 WO2001039793 A3 WO 2001039793A3 EP 0011873 W EP0011873 W EP 0011873W WO 0139793 A3 WO0139793 A3 WO 0139793A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
sema7a
pharmaceutical compositions
compositions containing
sema7
Prior art date
Application number
PCT/EP2000/011873
Other languages
French (fr)
Other versions
WO2001039793A2 (en
Inventor
Stephen Dudley Holmes
Ceri John Lewis
Original Assignee
Smithkline Beecham Plc
Stephen Dudley Holmes
Ceri John Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9928329.3A external-priority patent/GB9928329D0/en
Priority claimed from GB0022572A external-priority patent/GB0022572D0/en
Application filed by Smithkline Beecham Plc, Stephen Dudley Holmes, Ceri John Lewis filed Critical Smithkline Beecham Plc
Priority to AU26695/01A priority Critical patent/AU2669501A/en
Publication of WO2001039793A2 publication Critical patent/WO2001039793A2/en
Publication of WO2001039793A3 publication Critical patent/WO2001039793A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of Sema7 A polypeptides and polynucleotides in the design of protocols for the treatment of autoimmune disorders, chronic obstructive pulmonary disease, inflammation, psoriasis, wound healing, tissue repair, irritable bowel syndrome, stroke, atherosclerosis, cancer among others, and diagnostic assays for such conditions. Also disclosed are methods for producing such polypeptides by recombinant techniques.
PCT/EP2000/011873 1999-11-30 2000-11-28 Pharmaceutical compositions containing sema7a polypeptides WO2001039793A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU26695/01A AU2669501A (en) 1999-11-30 2000-11-28 New use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9928329.3 1999-11-30
GBGB9928329.3A GB9928329D0 (en) 1999-11-30 1999-11-30 New use
GB0022572.2 2000-09-14
GB0022572A GB0022572D0 (en) 2000-09-14 2000-09-14 New use

Publications (2)

Publication Number Publication Date
WO2001039793A2 WO2001039793A2 (en) 2001-06-07
WO2001039793A3 true WO2001039793A3 (en) 2001-11-29

Family

ID=26245000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011873 WO2001039793A2 (en) 1999-11-30 2000-11-28 Pharmaceutical compositions containing sema7a polypeptides

Country Status (2)

Country Link
AU (1) AU2669501A (en)
WO (1) WO2001039793A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006898A2 (en) * 2002-07-11 2004-01-22 Sema Aps Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
KR101967417B1 (en) 2008-11-10 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 Novel lipids and compositions for the delivery of therapeutics
CN110156890B (en) * 2019-04-09 2021-02-02 苏州大学 Semaphorin7A monoclonal antibody and application thereof in preparation of drugs for treating inflammatory diseases
MY190626A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053065A1 (en) * 1997-05-19 1998-11-26 Genetics Institute, Inc. Human semaphorin e and polynucleotides encoding it
DE19729211A1 (en) * 1997-07-09 1999-01-14 Hoechst Marion Roussel De Gmbh New semaphorin L proteins
WO1999038885A2 (en) * 1998-01-30 1999-08-05 Smithkline Beecham Plc Sbsemvl polypeptides, being members of the semaphorin protein family, and polynucleotides encoding the same
WO1999045114A2 (en) * 1998-03-03 1999-09-10 Zymogenetics, Inc. Human semaphorin zsmf-7
WO1999058676A2 (en) * 1998-05-14 1999-11-18 Immunex Corporation Semaphorin polypeptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053065A1 (en) * 1997-05-19 1998-11-26 Genetics Institute, Inc. Human semaphorin e and polynucleotides encoding it
DE19729211A1 (en) * 1997-07-09 1999-01-14 Hoechst Marion Roussel De Gmbh New semaphorin L proteins
WO1999038885A2 (en) * 1998-01-30 1999-08-05 Smithkline Beecham Plc Sbsemvl polypeptides, being members of the semaphorin protein family, and polynucleotides encoding the same
WO1999045114A2 (en) * 1998-03-03 1999-09-10 Zymogenetics, Inc. Human semaphorin zsmf-7
WO1999058676A2 (en) * 1998-05-14 1999-11-18 Immunex Corporation Semaphorin polypeptides

Also Published As

Publication number Publication date
AU2669501A (en) 2001-06-12
WO2001039793A2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
EP2292649A3 (en) Therapeutic epitopes and uses thereof
EP1082433A4 (en) Interleukins-21 and 22
EP1847548A3 (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
BR9910396A (en) Polynucleotide (s) and basb029 polypeptides from neisseria meningitidis
CA2266608A1 (en) Combination composition in the form of nutritional supplement or pharmaceutical composition for the prevention and therapeutical treatment of degenerative or inflammatory articular disorders
WO2001039793A3 (en) Pharmaceutical compositions containing sema7a polypeptides
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
EP1650221A3 (en) Novel compounds
EP0867509A3 (en) Tumor necrosis related receptor, TR5
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
BR9911601A (en) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
EP1443055A3 (en) Interleukins-21 and 22
WO2001000811A8 (en) 17867, a novel human aminopeptidase
WO2003059248A3 (en) Pigment epithelium derived factor from human plasma and methods of use thereof
WO2001023590A3 (en) 22196, a novel human aminopeptidase
BR9914492A (en) Moraxella catarrhalis basb034 polypeptides and their uses
WO2002040654A3 (en) A human serpin secreted from lymphoid cells lsi-01
CN207168559U (en) Fracture internal fixaiion axial pressure sliding groove steel plate
WO2000043519A3 (en) Neisseria meningitidis polypeptides
WO2001044446A3 (en) Further human alcohol dehydrogenases
EP0897009A3 (en) HKABY60 polypeptides
EP0875577A3 (en) Novel membrane-type matrix metalloproteinase-5 gene
EP0887406A3 (en) A member of the FRZB family, franzzled
WO2001043759A3 (en) Use of 11cby popypeptides and polynuceotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP